Related Experiment Videos

Cytotoxic and cancerostatic effect of 1,4-dithiaanthraquinone-2,3-dicarbonitrile

Neoplasma
|January 1, 1978
PubMed

Insights

1,4-Dithiaanthraquinone-2,3-dicarbonitrile (DTA) shows significant cytostatic effects on eukaryotic cells, including cancer cells. DTA inhibits biosynthesis and energy metabolism, demonstrating cancerostatic potential against Ehrlich ascites carcinoma in mice.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pharmacology

Background:

  • Eukaryotic cells, including HeLa cells, fungi, protozoa, and algae, are susceptible to cytostatic agents.
  • Ehrlich ascites carcinoma (EAC) is a model for studying cancer cell metabolism and drug response.

Purpose of the Study:

  • To investigate the cytostatic and cancerostatic effects of 1,4-Dithiaanthraquinone-2,3-dicarbonitrile (DTA).
  • To elucidate the mechanism of DTA's action on cancer cell biosynthesis and energy metabolism.

Main Methods:

  • Assessing the cytostatic effects of DTA on various eukaryotic cell types.
  • Measuring the incorporation of 14C-adenine and 14C-valine in EAC cells exposed to DTA.
  • Analyzing the impact of DTA on glucose consumption and lactate formation in EAC cells.
  • Evaluating the transplantability and cancerostatic effect of DTA in a murine EAC model.

Main Results:

  • DTA demonstrated significant cytostatic effects on HeLa cells, moulds, yeasts, protozoa, and algae.
  • DTA inhibited 14C-adenine and 14C-valine incorporation in EAC cells in a dose-dependent manner.
  • DTA interfered with EAC cell energy metabolism, specifically glycolysis, inhibiting glucose consumption and lactate production.
  • DTA treatment led to a loss of EAC cell transplantability and exhibited a cancerostatic effect in mice.

Conclusions:

  • 1,4-Dithiaanthraquinone-2,3-dicarbonitrile (DTA) exhibits potent cytostatic and cancerostatic properties.
  • DTA's mechanism involves the inhibition of essential biosynthetic pathways and energy metabolism, particularly glycolysis.
  • DTA represents a potential therapeutic agent for Ehrlich ascites carcinoma.

Related Concept Videos